AIM Company Profile

Below is the information we hold on the AIM company you have chosen to view. As a registered user, you can can view the Share Price, any public documents or presentations on the AIM company plus any additional details. Click on the share price ‘Block’ and you can view extended charting and share information. ‘Bookmark’ the company to your own portfolio, print off the page details and download as a ‘pdf’. You can also rate this AIM company by simply clicking the ‘star’ rating. If we hold news on this company, relevant articles will be displayed for you to view. Note: All share information is subject to a 15min. delay.

TRADE SHARES IN THIS AIM COMPANY

VALIRX

3.7
  1. Pharmaceuticals & Biotechnology
  2. » VALIRX
Share Price
Share Activity:
×
Key metrics
Market Cap
PE Ratio
PEG Ratio
EPS
Beta
Dividends
Dividend Rate
Dividend Yield
Ex Dividend Date
50 Days Moving Average
200 Days Moving Average
Key data
Symbol
Name
Bid
Ask
Last Price
Change
52 Week Low
52 Week High
Symbol Name Last Price Change % Change Day Low Day High

Click to View Charting

Research
You must be logged in to see this info
Key Company Info.
Company Description:

ValiRx plc, a biotechnology oncology focused company, engages in developing novel treatments for cancer and associated biomarkers in the United Kingdom. Its proprietary GeneICE technology enables the selective silencing of specific genes by targeted histone deacetylation leading to chromatin condensation. The company's lead drug candidates include VAL201, an anti-cancer therapeutic that is in Phase I/II trials for the treatment of prostate cancer and other indications of hormone induced unregulated growth, including endometriosis; VAL301, a reformulation of VAL201, which is in pre-clinical development for the non-invasive and better tolerated treatment of endometriosis; and VAL401, a reformulation of generic drug Risperidone, which has completed Phase II clinical trials for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL101, a therapeutic based on GeneICE platform that acts to target and switch off the Bcl-2 gene, a protein that is implicated carcinomas. It has licensing collaborations with Imperial Innovations Group plc, Cancer Research UK, and University College London Hospital. ValiRx plc was incorporated in 2000 and is based in London, the United Kingdom.

Active: Trading
EPIC:

VAL

List date: 3rd October 2006 00:00
Region:

London

Advisors
Nominated Advisor:

Cairn Financial Advisers LLP

Broker:

Northland Capital Partners Limited;Beaufort Securities Ltd

Contact Information
You must be logged in to see this info

If this profile is about your AIM company, but the information is limited you can add to the information we hold. The company displayed HERE is a typical example of the type of information we can display about your company. Good promotion of your AIM listed company is critical for exposure to potential investors and liquidity in shares. Get in touch HERE if you would like to know more about how we can help promote your AIM listed company.